Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMHVBG1)

Drug Name
Naftifine Drug Info
Synonyms
Naftifin; Naftifina; Naftifinum; Naftifine HCl; Naftifina [INN-Spanish]; Naftifine (INN); Naftifine [INN:BAN]; Naftifinum[INN-Latin]; Naftin (TN); SN 105-843; N-cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride; N-Methyl-N-(1-naphthyl methyl)-3-phenyl-2-propen-1-amine(E), hydrochloride; (2E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine; (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine; (E)-N-Cinnamyl-N-methyl-1-naphthalinmethylamin; (E)-N-Cinnamyl-N-methyl-1-naphthylmethylamin; (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine
Therapeutic ClassAntifungal Agents
Cross-matching ID
PubChem CID
47641
ChEBI ID
CHEMBL626
CAS Number
CAS 65472-88-0
TTD Drug ID
D00HPK

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.10 0.00e+0 34/36 (94.44%) POLE2;MCM2;MCM6;...
Ribosome biogenesis in eukaryotes 2.00 1.13e-2 52/108 (48.15%) NVL;POP7;RPP38;...
Proteasome 1.96 7.51e-3 44/46 (95.65%) PSMA2;PSMC2;PSMA7;...
Cell cycle 1.85 1.50e-2 110/124 (88.71%) CCNB2;PLK1;MCM2;...
Citrate cycle (TCA cycle) 1.81 1.80e-2 30/30 (100%) DLD;PCK1;SUCLA2;...
Protein digestion and absorption 1.80 1.50e-2 78/103 (75.73%) COL10A1;COL3A1;COL17A1;...
RNA degradation 1.75 2.57e-2 53/79 (67.09%) LSM5;LSM8;EDC3;...
Progesterone-mediated oocyte maturation 1.75 2.35e-2 75/100 (75%) CCNB2;PLK1;IGF1;...
One carbon pool by folate 1.70 3.59e-2 15/20 (75%) SHMT1;TYMS;GART;...
Oxidative phosphorylation 1.69 3.53e-2 93/133 (69.92%) PPA1;ATP5F1C;NDUFAB1;...
Homologous recombination 1.66 4.16e-2 35/41 (85.37%) RPA3;RAD51C;BLM;...
Mismatch repair 1.66 4.00e-2 22/23 (95.65%) EXO1;RPA3;MSH2;...
Collecting duct acid secretion 1.64 4.91e-2 22/27 (81.48%) ATP6V1B1;ATP6V1A;CA2;...
Neutrophil extracellular trap formation -1.79 3.63e-2 101/189 (53.44%) TLR2;CYBB;FPR2;...
Melanogenesis -1.84 3.96e-2 74/101 (73.27%) PLCB2;PRKACA;DVL1;...
Other glycan degradation -1.99 0.00e+0 13/18 (72.22%) ENGASE;HEXB;MAN2B2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 6.66uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H